心通医疗-B(02160.HK) 公布关连交易,向微创投资及上海佐擎收购上海佐心余下49%股权至全资拥有,后者主要专注于左心耳相关医疗器材,拥有两个自主研发的产品—AnchorMan左心耳封堵系统及AnchorMan左心耳导引系统,现金总代价1.71亿人民币,将以内部资源支付。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.